Sectoral Asset Management’s Vaxcyte PCVX Stock Holding History

Sectoral Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,205	Closed	-$151K	–	80
2025 Q3	$151K	Hold	4,205	–	–	0.09%	79
2025 Q2	$137K	Sell	4,205 -16,835	-80%	-$552K	0.09%	91
2025 Q1	$794K	Buy	21,040 +2,090	+11%	+$167K	0.62%	43
2024 Q4	$1.55M	Buy	18,950 +4,410	+30%	+$438K	1.04%	27
2024 Q3	$1.66M	Sell	14,540 -19,190	-57%	-$1.73M	0.98%	28
2024 Q2	$2.55M	Buy	33,730 +25,230	+297%	+$1.72M	1.04%	28
2024 Q1	$581K	Buy	8,500 +450	+6%	+$31.2K	0.23%	64
2023 Q4	$506K	Sell	8,050 -113,180	-93%	-$5.88M	0.22%	78
2023 Q3	$6.18M	Buy	121,230 +12,253	+11%	+$604K	1.2%	28
2023 Q2	$5.44M	Buy	108,977 +48,977	+82%	+$2.32M	0.91%	50
2023 Q1	$2.25M	Hold	60,000	–	–	0.43%	78
2022 Q4	$2.88M	Buy	+60,000	New	+$2.35M	0.56%	70

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sectoral Asset Management's PCVX Position: Q4 2025 in Review

Sectoral Asset Management sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 4,205 shares — an estimated $151K sold.

Sectoral Asset Management first reported a position in PCVX in Q4 2022 and held it in 12 quarters. The position peaked at $6.18M in Q3 2023. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Sectoral Asset Management reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Sectoral Asset Management sold 4,205 Vaxcyte shares in Q4 2025, an estimated $151K.
Sectoral Asset Management first reported a position in Vaxcyte in Q4 2022 and held it in 12 quarters.
Sectoral Asset Management's Vaxcyte position peaked at $6.18M in Q3 2023.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Sectoral Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.